Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology

Search Medical Condition
Please enter condition
Please choose location

Chordoma Clinical Trials

A listing of Chordoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (18) clinical trials

A Phase II Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

This is a Phase II, multicenter, open-label, single arm, 2-stage study of tazemetostat 800 mg BID administered orally in continuous 28 day cycles. Screening of subjects to determine eligibility for the study will be performed within 21 days of the first planned dose of tazemetostat. Eligible subjects will be enrolled ...

Phase

Study of Individuals and Families at High Risk for Cancer

OBJECTIVES: - Identify individuals at high risk of cancer, especially due to personal or family medical history. - Evaluate and define clinical spectrum of disease in syndromes predisposing to cancer. - Quantify risks of tumors in family members. - Map, clone, and determine function of tumor susceptibility genes. - Identify ...

Phase N/A

Collecting and Storing Tissue Blood and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

OBJECTIVES: I. Collect human tumor tissue and other biological specimens (blood, serum, and bone marrow) from patients with rhabdomyosarcoma or non-rhabdomyosarcoma soft tissue sarcoma diagnosed and/or treated at a Children's Oncology Group (COG) member institution. II. Provide a repository for storage of tissue and other biological specimens collected by COG ...

Phase N/A

HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors

Patients with relapsed solid tumors such as sarcomas and neuroblastoma have a poor survival, generally < 20%. There is an urgent need for new treatments that are safe and effective. HSV1716, an oncolytic virus, is a mutant herpes simplex virus (HSV) type I, deleted in the RL1 gene which encodes ...

Phase

Natural History Study of Patients With Central Nervous System Tumors Being Evaluated at the National Institutes of Health

OBJECTIVES: - Evaluate patients with CNS tumors who are probable future candidates for NCI phase I and II protocols. - Follow patients with CNS tumors that are representative of important scientific and/or clinical principles. - Attain a steady flow of patients with CNS tumors at the NIH, which will help ...

Phase N/A

Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes

Background Chordoma is a rare, slow growing, often fatal bone cancer derived from notochord remnants. It occurs in the axial skeleton (skull base, vertebrae, sacrum, coccyx), is more frequent in males, and has a median age at diagnosis of 58.5 years, with a wide age range. This typically sporadic tumor ...

Phase N/A

Ion Irradiation of Sacrococcygeal Chordoma

The primary objective of this trial is safety and feasibility of hypofractionated irradiation in patients with sacrococcygeal chordoma using protons or carbon ions in raster scan technique for primary or additive treatment after R2 resection. The evaluation is therefore based on the proportion of treatments without Grade 3-5 toxicity (CTCAE, ...

Phase

Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base

The study is a prospective randomised clinical phase III trial. The trial will be carried out at Heidelberger Ionenstrahl-Therapie (HIT) centre as monocentric trial. Proton therapy is the gold standard in the treatment of skull base chordomas. However, high-LET beams such as carbon ions theoretically offer biologic advantages by enhanced ...

Phase

Identifying New Families With Multiple Members Affected by Chordoma

OBJECTIVES: - To determine the feasibility of conducting a larger study encompassing the remaining English-speaking patients at Massachusetts General Hospital with chordoma. - To identify new families with multiple members affected by chordoma to participate in clinical and gene mapping studies. OUTLINE: Patients complete a questionnaire about demographics (education, marital ...

Phase N/A

Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers

Background There are more than 130 identified primary tumors of the central nervous system (CNS). Most have an annual incidence of less than 1000 in the United States. Given the rarity of each of the tumors listed above, there is a paucity of proven therapies. Most of these neoplasms are ...

Phase